Featured Research

from universities, journals, and other organizations

Transplant programs produce high one-year survival rates

Date:
May 20, 2014
Source:
Cedars-Sinai Medical Center
Summary:
In the latest national report on organ transplant outcomes, patients receiving a new liver at one American hospital had excellent one-year survival outcomes, with 90% of liver transplant patients surviving beyond that important milestone. Patients receiving new kidneys at this medical center also did extremely well with 97 percent of them surpassing the one year bench mark.

In the latest national report on organ transplant outcomes, patients receiving a new liver at the Cedars-Sinai Comprehensive Transplant Center had the best one-year survival outcomes of all hospitals in the Los Angeles region, with 90% of liver transplant patients surviving beyond that important milestone. Patients receiving new kidneys at the medical center also did extremely well with 97 percent of them surpassing the one year bench mark.

"This is a very strong performance by our dedicated transplant teams and researchers at Cedars-Sinai," said Andrew S. Klein MD, MBA, the Esther and Mark Schulman Chair in Surgery and Transplantation Medicine. "At the Comprehensive Transplant Center, we have a commitment to include care for the very sickest, high risk patients in need of a lifesaving organ transplant."

The success with kidney transplant patients is particularly noteworthy given the number of very ill people who come to the medical center with a high probability of rejecting a donor organ because of high amounts of antibodies in their blood. Antibodies are protein molecules that are an important part of the body's immune defense system, but can cause rejection of a transplanted organ. Stanley C. Jordan, MD, director of Kidney Transplantation and Transplant Immunology, is a prominent pioneer in designing treatment approaches that have significantly reduce the amount of antibodies, thereby reducing the risk of organ rejection.

"This latest survival report is a great encouragement. The fact that nearly all of our kidney transplant patients are thriving one year later indicates the research and new treatment protocols we are developing and using can make the most meaningful difference for the people we treat," said Jordan.

The survival outcomes are rigorously compiled by the Scientific Registry of Transplant Recipients, a non-profit organization. The registry collects information from hospitals and donor procurement agencies across the nation to evaluate the scientific and clinical state of transplantation in the United States.

The lung transplant program at Cedars-Sinai is one of the few medical centers in Southern California with Medicare certification, and it accepts some of the sickest, most chronically ill lung patients from around the country. The latest one-year survival outcomes report is encouraging with nearly three-quarters of those transplanted doing well.

"We have assembled a great team of transplant surgeons and researchers here so we can offer patients in critical need of a lung transplant the highest level of care, with the expectation of the best possible outcomes for them," said Paul Noble, MD, director of the Women's Guild Lung Institute at Cedars-Sinai and chair of the Department of Medicine.

Cedars-Sinai leads the nation in the number of adult heart transplants done annually, and nearly 90 percent of those patients are alive and doing well one year after getting a new heart according to the latest report.

"Organs for transplantation are such a precious resource, it is imperative that we continue to do all we can to maximize transplant success, improving the longevity and quality of our patients' lives," said Klein.


Story Source:

The above story is based on materials provided by Cedars-Sinai Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Cedars-Sinai Medical Center. "Transplant programs produce high one-year survival rates." ScienceDaily. ScienceDaily, 20 May 2014. <www.sciencedaily.com/releases/2014/05/140520152953.htm>.
Cedars-Sinai Medical Center. (2014, May 20). Transplant programs produce high one-year survival rates. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2014/05/140520152953.htm
Cedars-Sinai Medical Center. "Transplant programs produce high one-year survival rates." ScienceDaily. www.sciencedaily.com/releases/2014/05/140520152953.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins